Quantitative GLP-1 receptor imaging correlated to ex vivo distribution of In-111-exendi
Completed
- Conditions
- 10018424diabetes
- Registration Number
- NL-OMON44912
- Lead Sponsor
- ucleaire Geneeskunde
- Brief Summary
Trial ended prematurely
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 12
Inclusion Criteria
Scheduled for partial or complete pancreatectomy or complete drainage procedure in case of chronic pancreatitis, Intraductal papillary mucinous neoplasm (IPMN) or pancreatic cancer at Radboudumc
Exclusion Criteria
* Resection of only small part of the pancreas without possibility to safely sample other pancreatic parts
* Breast feeding
* Pregnancy or the wish to become pregnant within 6 months
* Creatinine clearance below 40ml/min
* Liver disease defined as aspartate aminotransferase or alanine aminotransferase level of more than three times the upper limit of normal range
* Age < 18 years
previous treatment with synthetic Exendin (Exenatide, Byetta®) or Dipeptidyl-Peptidase IV inhibitors
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Quantitative determination of the uptake of In-111-exendin into the pancreas in<br /><br>all subjects as determined by 3D SPECT imaging in order to correlate the uptake<br /><br>to the ex vivo distribution and accumulation of the tracer in the pancreas with<br /><br>the BCM. </p><br>
- Secondary Outcome Measures
Name Time Method